3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Status
Recruiting
31
Unknown
18
Not yet recruiting
17
Completed
16
Active not recruiting
10
Terminated
9
Withdrawn
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
Other solid neoplasm
3
Gastrointestinal
3
Thoracic
2
Sarcoma
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Breast
1
Conditions
Small Cell Lung Carcinoma
1
Sarcoma
1
Mesothelioma, Malignant
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Anus Neoplasms
1
Interventions
Carboplatin
40
Cisplatin
37
Pemetrexed
33
Radiotherapy
23
Paclitaxel
22
pembrolizumab
20
durvalumab
19
Docetaxel
19
Gemcitabine
18
Nivolumab
15
Radiosurgery
14
Etoposide
13
atezolizumab
11
Erlotinib Hydrochloride
11
Taxes
8
Magnetic Resonance Spectroscopy
8
Drug Therapy
8
Bevacizumab
8
Cyclophosphamide
7
Platinum
6
Gefitinib
6
Surveys and Questionnaires
5
Biopsy
5
130-nm albumin-bound paclitaxel
5
1,2-diaminocyclohexaneplatinum II citrate
5
sotorasib
4
Ramucirumab
4
Radiation
4
Immunotherapy
4
Fluorodeoxyglucose F18
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Withdrawn
×
tislelizumab
×
Thoracic
×
Clear all
NCT05791097
2023-07-24
AdvanTIG-306
Novartis
Phase 3
Withdrawn
NCT05582031
2023-06-07
REFIT-MSS
Translational Research in Oncology
Phase 2
Withdrawn